Fragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Fragile X Syndrome Clinical Trial Report Overview
A total of 110 fragile X syndrome clinical trials were conducted as of March 2024. The fragile X syndrome clinical trial report provides a comprehensive understanding of the fragile X syndrome clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials.
Key Regions | · North America
· Europe · Asia-Pacific · Middle East and Africa · South and Central America |
Key Countries | · The US
· Australia · Canada · Spain · The UK |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · F. Hoffmann-La Roche Ltd
· Novartis AG · Seaside Therapeutics LLC (Inactive) · Harmony Biosciences Holdings Inc · Shionogi & Co Ltd |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Fragile X Syndrome Clinical Trials Segmentation by Regions and Countries
As of March 2024, North America led the fragile X syndrome clinical trials landscape with more than 55% of the clinical trials conducted there
The key regions considered for fragile X syndrome clinical trials analysis are North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.
In the country-wise analysis, the US had the highest number of fragile X syndrome clinical trials as of March 2024. The UK had the highest average patient enrollment in fragile X syndrome clinical trials during the same time.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the US held the highest proportion of Fragile X Syndrome to Genetic Disorders clinical trials as of March 2024.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Indonesia held the highest proportion of Fragile X Syndrome to Genetic Disorders clinical trials as of March 2024.
Fragile X Syndrome Clinical Trials Analysis by Regions, 2024 (%)
Buy the Full Report for More Regional Insights into the Fragile X Syndrome Clinical Trials
Fragile X Syndrome Clinical Trials Segmentation by Sponsor Types
The key sponsor types for fragile X syndrome clinical trials are company, institution, and the government. As of March 2024, the company sponsor type conducted more than 56% of fragile X syndrome clinical trials.
Fragile X Syndrome Clinical Trials Analysis by Sponsor Types, 2024 (%)
Buy the Full Report for More Sponsor Type Insights into the Fragile X Syndrome Clinical Trials
Fragile X Syndrome Clinical Trials - Competitive Landscape
In 2024, F. Hoffmann-La Roche Ltd, Novartis AG, and Seaside Therapeutics LLC conducted the highest number of fragile X syndrome clinical trials
A few of the leading sponsors for fragile X syndrome clinical trials are:
- Hoffmann-La Roche Ltd
- Novartis AG
- Seaside Therapeutics LLC (Inactive)
- Harmony Biosciences Holdings Inc
- Shionogi & Co Ltd
Fragile X Syndrome Clinical Trials Analysis by Sponsors, 2024 (%)
Buy the Full Report to Know More about the Leading Sponsors of Fragile X Syndrome Clinical Trials
Segments Covered in the Report
Fragile X Syndrome Clinical Trials Regional Outlook (2024)
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South and Central America
Fragile X Syndrome Clinical Trials Country Outlook (2024)
- The US
- Australia
- Canada
- Spain
- The UK
Fragile X Syndrome Clinical Trials Sponsor Type Outlook (2024)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Formulate key business strategies with regard to investment.
- Identify prominent locations for conducting clinical trials which saves time and cost.
- Get top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Understand trial count and enrollment trends by country in the global therapeutics market.
- Interpret the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Understand clinical trial assessment of the indication on a global, regional, and country level.
Novartis AG
Seaside Therapeutics LLC (Inactive)
Harmony Biosciences Holdings Inc
Shionogi & Co Ltd
Neuren Pharmaceuticals Ltd
Jazz Pharmaceuticals Plc
Ovid Therapeutics Inc
Anavex Life Sciences Corp
Arcturus Therapeutics Holdings Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of fragile X syndrome clinical trials in March 2024?
North America accounted for the highest number of fragile X syndrome clinical trials as of March 2024.
-
Which country conducted the highest number of fragile X syndrome clinical trials in March 2024?
The US conducted the highest number of fragile X syndrome clinical trials as of March 2024.
-
Which sponsor type was the most prominent in the fragile X syndrome clinical trials in March 2024?
As of March 2024, company sponsor type conducted most of the fragile X syndrome clinical trials.
-
Which are the leading sponsors of fragile X syndrome clinical trials?
A few of the leading sponsors of fragile X syndrome clinical trials are F. Hoffmann-La Roche Ltd, Novartis AG, Seaside Therapeutics LLC, Harmony Biosciences Holdings Inc, and Shionogi & Co Ltd, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.